Prof. Cédric B, Soufiane Boumahdi and others from the IRIBHM, Brussels B-1070, Belgium has published a research paper in the 10 July 2014 Nature (I.F: >35) stating that “SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma.”
In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Natural product-based therapy for squamous cell carcinoma: Rhamnetin, an O-methylated flavonol isolated from cloves, inhibits tumor-initiating cells and cancer stem cells via down regulation of Sox2. Remarkably, a significant percentage of human cancer stem cells over express Sox-2, suggesting that inhibition of its activity may erradicate the tumor-initiating cancer stem cells. Together, this study suggests that pharmacological formulations encompassing “Rhamnetin or its analogues” can be used in the treatment of human cancers.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Natural product-based therapy for squamous cell carcinoma: Rhamnetin, an O-methylated flavonol isolated from cloves, inhibits tumor-initiating cells and cancer stem cells via down regulation of Sox2, 16/July/2014, 8.39 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
